Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human Activin RIIB / ACVR2B Protein, His tag, 2x 500µg  

Recombinant human Activin RIIB / ACVR2B Protein, His tag, 2x 500µg

Recombinant human Activin RIIB / ACVR2B Protein, Ser19-Thr137, produced in human 293 cells (HEK293), His Tag

Synonym
Recombinant human Protein, ACVR2B, ACTRIIB, ACTR?B, ActR-IIB, ACTR-IIB, MGC116908, Activin receptor type-2B

More details

ACB-H5226-1K

Availability: within 7 days

1 100,00 €

Background
Activin receptor type-2B (ACVR2B),is also known as ActR-IIB and MGC116908, ACVR2B is an activin type 2 receptor. Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases. This gene encodes activin A type IIB receptor, which displays a 3- to 4-fold higher affinity for the ligand than activin A type II receptor. Defects in ACVR2B are the cause of visceral heterotaxy autosomal type 4 (HTX4).[1,2]

Source
Recombinant human ACVR2B Protein (rhACVR2B) Ser19-Thr137 (Accession# NP_001097)was produced in human 293 cells (HEK293)

Molecular Characterization
rhACVR2B contains C-terminal polyhistidine tag and has a calculated MW of 14.5 kDa. The predicted N-terminus is Ser19. DTT-reduced protein migrates as 25-32 kDa polypeptide in SDS-PAGE.

Endotoxin
Less than 1.0 EU per µg of the rhACVR2B by the LAL method.

Purity
>97% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 µm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
N / A

References

(1) Attisano, L. et al., 1996, Mol. Cell. Biol. 16: 1066-1073.
(2) Woodruff, T.K. (1998) Biochem. Pharmacology 55:953 .